On August 24, 2026, Autonomix Medical entered into a warrant inducement agreement requiring the holder of existing Series D-1 and D-2 warrants to exercise them for 857,462 shares at $5.75 per share. The company anticipates receiving approximately $4.9 million in gross proceeds from this cash exercise. In consideration, Autonomix issued new unregistered Series E-1 and E-2 warrants to purchase a combined 1,071,826 shares at an exercise price of $6.25 per share. These new warrants are immediately exercisable with a five-year term and include beneficial ownership limitations and fundamental transaction protections. Maxim Group LLC served as the financial advisor for the transaction.
